数据链接：
官方服务：
资源简介：
Serious adverse events by randomisation arm.
应用场景：
创建时间：
2018-11-27
相关数据集
A real-world disproportionality analysis of ospemifene: data mining of the public version of FDA adverse event reporting system
Ospemifene has been authorized for the treatment of vulvovaginal atrophy (VVA). This study wasto evaluate adverse events (AEs) associated with ospemifene by data mining the US Food and Drug Administra
DataCite Commons2024-02-27 更新130
Results of EUS-guided puncture and adverse events.
Results of EUS-guided puncture and adverse events.
Figshare2019-06-06 更新60
Treatment-related Adverse Events (AE).
Events are listed alphabetically with percentages indicating percent of total AEs. Grading is according to standard Common Terminology Criteria for Adverse Events (CTCAE) grading.
Figshare2015-12-02 更新50
A Pharmacovigilance Study of adverse events associated with polymyxins based on the U.S. Food and Drug Administration adverse event reporting system (FAERS) database
Polymyxins, including both colistin and polymyxin B (PMB), have regained clinical attention as last-line treatment options for treating infections caused by multidrug-resistant (MDR) gram-negative bac
DataCite Commons2026-04-21 更新120
Disproportionality Analysis of Fondaparinux-Associated Adverse Events Based on the FDA Adverse Event Reporting System (FAERS)
This dataset contains the minimal underlying data used to reproduce the findings of the study titled “Safety profile of fondaparinux based on the FAERS database: a disproportionality analysis”. The da
DataCite Commons2025-11-16 更新60
